WO2015101414A3 - Artificial nucleic acid molecules - Google Patents

Artificial nucleic acid molecules Download PDF

Info

Publication number
WO2015101414A3
WO2015101414A3 PCT/EP2014/003480 EP2014003480W WO2015101414A3 WO 2015101414 A3 WO2015101414 A3 WO 2015101414A3 EP 2014003480 W EP2014003480 W EP 2014003480W WO 2015101414 A3 WO2015101414 A3 WO 2015101414A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
utr
artificial nucleic
acid sequence
acid molecules
Prior art date
Application number
PCT/EP2014/003480
Other languages
French (fr)
Other versions
WO2015101414A2 (en
Inventor
Andreas Thess
Original Assignee
Curevac Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020167020951A priority Critical patent/KR102399799B1/en
Priority to JP2016543590A priority patent/JP6704850B2/en
Priority to EP14854873.8A priority patent/EP3090053B1/en
Priority to BR112016014462A priority patent/BR112016014462A2/en
Priority to RU2016131391A priority patent/RU2717986C2/en
Priority to ES14854873T priority patent/ES2712092T3/en
Priority to AU2014375402A priority patent/AU2014375402B2/en
Application filed by Curevac Gmbh filed Critical Curevac Gmbh
Priority to CN201480065035.1A priority patent/CN105874072A/en
Priority to MX2016008551A priority patent/MX2016008551A/en
Priority to DK14854873.8T priority patent/DK3090053T3/en
Priority to CA2927862A priority patent/CA2927862C/en
Priority to EP20202943.5A priority patent/EP3842537A1/en
Priority to SG11201603144QA priority patent/SG11201603144QA/en
Priority to EP18199987.1A priority patent/EP3495486B1/en
Publication of WO2015101414A2 publication Critical patent/WO2015101414A2/en
Publication of WO2015101414A3 publication Critical patent/WO2015101414A3/en
Priority to US15/195,934 priority patent/US10047375B2/en
Priority to US16/030,018 priority patent/US11254951B2/en
Priority to US17/576,583 priority patent/US20220136001A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-untranslated region element (3'-UTR) element comprising a nucleic acid sequence which is derived from the 3'-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3'-UTR element comprising a nucleic acid sequence which is derived from the 3'-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3'-UTR element.
PCT/EP2014/003480 2013-12-30 2014-12-30 Artificial nucleic acid molecules WO2015101414A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SG11201603144QA SG11201603144QA (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
EP14854873.8A EP3090053B1 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
BR112016014462A BR112016014462A2 (en) 2013-12-30 2014-12-30 artificial nucleic acid molecules
RU2016131391A RU2717986C2 (en) 2013-12-30 2014-12-30 Artificial molecules of nucleic acid
ES14854873T ES2712092T3 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
AU2014375402A AU2014375402B2 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
DK14854873.8T DK3090053T3 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
CN201480065035.1A CN105874072A (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
MX2016008551A MX2016008551A (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules.
KR1020167020951A KR102399799B1 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
CA2927862A CA2927862C (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
EP20202943.5A EP3842537A1 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
JP2016543590A JP6704850B2 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecule
EP18199987.1A EP3495486B1 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
US15/195,934 US10047375B2 (en) 2013-12-30 2016-06-28 Artificial nucleic acid molecules
US16/030,018 US11254951B2 (en) 2014-12-30 2018-07-09 Artificial nucleic acid molecules
US17/576,583 US20220136001A1 (en) 2013-12-30 2022-01-14 Artificial nucleic acid molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/003946 2013-12-30
EP2013003946 2013-12-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/195,934 Continuation US10047375B2 (en) 2013-12-30 2016-06-28 Artificial nucleic acid molecules

Publications (2)

Publication Number Publication Date
WO2015101414A2 WO2015101414A2 (en) 2015-07-09
WO2015101414A3 true WO2015101414A3 (en) 2015-10-08

Family

ID=49920310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/003480 WO2015101414A2 (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules

Country Status (13)

Country Link
US (2) US10047375B2 (en)
JP (2) JP6704850B2 (en)
KR (1) KR102399799B1 (en)
CN (2) CN105874072A (en)
AU (1) AU2014375402B2 (en)
BR (1) BR112016014462A2 (en)
CA (1) CA2927862C (en)
DK (1) DK3090053T3 (en)
ES (1) ES2712092T3 (en)
MX (2) MX2016008551A (en)
RU (1) RU2717986C2 (en)
SG (2) SG10201903381TA (en)
WO (1) WO2015101414A2 (en)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
KR102128248B1 (en) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
RU2658490C2 (en) * 2012-03-27 2018-06-21 Кьюрвак Аг Artificial nucleic acid molecules for improved protein or peptide expression
SG11201405545XA (en) * 2012-03-27 2014-11-27 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
EA201492055A1 (en) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. INHALATIVE DELIVERY OF mRNA IN TIGHTNESS CELL TARGETS
DK2958588T3 (en) 2013-02-22 2017-11-20 Curevac Ag Combination of vaccination and inhibition of PD-1 pathway
AU2014239184B2 (en) 2013-03-14 2018-11-08 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
DK2968586T3 (en) 2013-03-14 2018-10-08 Translate Bio Inc CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
EP3757570B1 (en) 2013-03-15 2023-10-11 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
EP3971287A1 (en) 2013-07-11 2022-03-23 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
RU2712743C2 (en) 2013-08-21 2020-01-30 Куревак Аг Rabies vaccine
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
BR112016003361A2 (en) 2013-08-21 2017-11-21 Curevac Ag respiratory syncytial virus vaccine (rsv)
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
JP6704850B2 (en) 2013-12-30 2020-06-03 キュアバック アーゲー Artificial nucleic acid molecule
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
ES2727776T3 (en) 2014-06-10 2019-10-18 Curevac Ag Method to improve RNA production
ES2834556T3 (en) 2014-06-25 2021-06-17 Acuitas Therapeutics Inc Novel lipid and lipid nanoparticle formulations for nucleic acid delivery
PL3708668T3 (en) 2014-12-12 2022-12-05 Curevac Ag Artificial nucleic acid molecules for improved protein expression
KR102580696B1 (en) * 2014-12-30 2023-09-19 큐어백 에스이 Novel artificial nucleic acid molecules
EP4353257A2 (en) 2015-04-13 2024-04-17 CureVac Manufacturing GmbH Method for producing rna compositions
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
MX2017013321A (en) 2015-04-22 2018-07-06 Curevac Ag Rna containing composition for treatment of tumor diseases.
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
DK3294885T3 (en) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh METHOD OF PREPARING RNA
DK3294326T3 (en) 2015-05-15 2021-05-31 Curevac Ag PRIME-BOOST REGIMES INCLUDING SUBMISSION OF AT LEAST ONE MRNA CONSTRUCTION
CN107635587A (en) 2015-05-20 2018-01-26 库瑞瓦格股份公司 Include long-chain RNA dry powder compositions
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
CN107873055B (en) 2015-05-29 2021-09-17 库瑞瓦格房地产有限公司 Method for producing and purifying RNA comprising at least one tangential flow filtration step
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
JP7072386B2 (en) 2015-06-29 2022-05-20 アクイタス セラピューティクス インコーポレイテッド Lipid and Lipid Nanoparticle Formulations for Nucleic Acid Delivery
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
WO2017036580A1 (en) 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
JP2018527003A (en) * 2015-09-17 2018-09-20 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Polynucleotide containing stabilized tail region
HRP20220156T1 (en) 2015-09-17 2022-04-15 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
ES2914225T3 (en) 2015-10-16 2022-06-08 Modernatx Inc Modified phosphate bond mRNA cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
CA3001014A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
MA47016A (en) 2015-10-22 2018-08-29 Modernatx Inc RESPIRATORY VIRUS VACCINES
CN108368028B (en) 2015-10-28 2021-09-03 爱康泰生治疗公司 Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
DK3394030T3 (en) 2015-12-22 2022-03-28 Modernatx Inc COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR RELEASE OF FUNDS
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
MX2018009917A (en) 2016-02-17 2019-08-14 Curevac Ag Zika virus vaccine.
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
KR102475301B1 (en) 2016-04-08 2022-12-09 트랜슬레이트 바이오 인코포레이티드 Multimeric coding nucleic acid and uses thereof
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP3452493A1 (en) 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
SI3458083T1 (en) 2016-05-18 2023-03-31 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
BR112018075479A2 (en) 2016-06-09 2019-03-19 Curevac Ag hybrid carriers for nucleic acid loading
JP2019522047A (en) 2016-06-13 2019-08-08 トランスレイト バイオ， インコーポレイテッド Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
US20200069599A1 (en) 2016-06-14 2020-03-05 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11253601B2 (en) 2016-07-11 2022-02-22 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. Respiratory virus nucleic acid vaccines
JP2020501545A (en) 2016-12-08 2020-01-23 キュアバック アーゲー RNA for treatment or prevention of liver disease
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
KR20190132405A (en) 2017-03-15 2019-11-27 모더나티엑스, 인크. Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
SG11201906297QA (en) 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3618859A4 (en) 2017-04-27 2021-05-05 Vanderbilt University Hepatitis c virus gene sequences and methods of use therefor
IL301115A (en) 2017-04-28 2023-05-01 Acuitas Therapeutics Inc Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US20210198200A1 (en) 2017-06-14 2021-07-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods of preparing modified rna
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
BR112020004351A2 (en) * 2017-10-19 2020-09-08 Curevac Ag artificial nucleic acid molecules
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
EP3727428A1 (en) 2017-12-20 2020-10-28 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
SG11202005760PA (en) 2017-12-21 2020-07-29 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. Rsv rna vaccines
AU2019243155A1 (en) * 2018-03-27 2020-10-15 Factor Bioscience Inc. Nucleic acid-based therapeutics
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
AU2020214843A1 (en) 2019-01-31 2021-08-19 Modernatx, Inc. Methods of preparing lipid nanoparticles
JP2022523117A (en) 2019-01-31 2022-04-21 モデルナティエックス インコーポレイテッド Vortex mixers and related methods, systems, and equipment
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN112190591B (en) * 2019-07-08 2021-12-17 中国农业科学院兰州兽医研究所 Use of ribosomal protein RPL13 inhibitor for the preparation of a medicament for inhibiting IRES-dependent translation of viral replication
CN115175698A (en) 2020-01-28 2022-10-11 摩登纳特斯有限公司 Coronavirus RNA vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
WO2021159040A2 (en) 2020-02-07 2021-08-12 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
MX2022012630A (en) 2020-04-09 2022-11-07 Suzhou Abogen Biosciences Co Ltd Lipid nanoparticle composition.
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
CN111621588A (en) * 2020-06-08 2020-09-04 华中农业大学 Molecular marker for breeding bright peel tomato variety and application thereof
WO2022002040A1 (en) 2020-06-30 2022-01-06 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CN114391008B (en) 2020-08-20 2024-05-03 苏州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
AU2021405281A1 (en) 2020-12-22 2023-07-06 CureVac SE Rna vaccine against sars-cov-2 variants
CN114717230A (en) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 Methods and nucleic acid molecules for cell-free and vector-free in vitro RNA transcription of fibroblast growth factor mRNA
CN114717238A (en) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 Methods and nucleic acid molecules for cell-free and vector-free in vitro RNA transcription of epidermal growth factor mRNA
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
JP2024503698A (en) 2021-01-15 2024-01-26 モデルナティエックス インコーポレイテッド Mutant strain-based coronavirus vaccine
CA3208303A1 (en) 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
JP2024511346A (en) 2021-03-15 2024-03-13 モデルナティエックス インコーポレイテッド Therapeutic use of SARS-COV-2 mRNA domain vaccines
AU2022258335A1 (en) 2021-04-13 2023-11-23 Modernatx, Inc. Respiratory virus combination vaccines
WO2022221440A1 (en) 2021-04-14 2022-10-20 Modernatx, Inc. Influenza-coronavirus combination vaccines
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
EP4204390A1 (en) 2021-05-24 2023-07-05 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CA3224175A1 (en) 2021-06-18 2022-12-22 Sanofi Multivalent influenza vaccines
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CA3231523A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
EP4204391A1 (en) 2021-10-08 2023-07-05 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AR127312A1 (en) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
CA3235867A1 (en) 2021-10-22 2023-04-27 Munir MOSAHEB Mrna vaccine composition
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
CA3238764A1 (en) 2021-11-23 2023-06-01 Siddharth Patel A bacteria-derived lipid composition and use thereof
WO2023102373A1 (en) 2021-11-30 2023-06-08 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
AU2022421841A1 (en) 2021-12-20 2024-06-27 Sail Biomedicines, Inc. Mrna therapeutic compositions
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023116804A1 (en) 2021-12-23 2023-06-29 苏州艾博生物科技有限公司 Lipid compound and lipid nanoparticle composition
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
TW202408567A (en) 2022-05-06 2024-03-01 法商賽諾菲公司 Signal sequences for nucleic acid vaccines
WO2023217267A1 (en) * 2022-05-13 2023-11-16 上海瑞宏迪医药有限公司 Nucleic acid construct comprising utr and use thereof
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024094876A1 (en) 2022-11-04 2024-05-10 Sanofi Methods for messenger rna tailing
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024126809A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna encoding influenza virus-like particle
WO2024126847A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna recombinant capping enzymes
CN116159127B (en) * 2023-01-17 2024-04-02 西安交通大学医学院第一附属医院 Use of acidic ribosomal protein P2 in the treatment of anxiety disorders
CN116004696B (en) * 2023-02-01 2024-03-29 郑州贝贝生物科技有限公司 3' -UTR (UTR) stem-loop added structure gene capable of being combined with IRES (IRES), application thereof and mRNA (messenger ribonucleic acid) expression system

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007590A2 (en) * 1999-07-27 2001-02-01 Syngenta Participations Ag Chimeric genes for plastid expression
WO2002098443A2 (en) * 2001-06-05 2002-12-12 Curevac Gmbh Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
WO2006022712A1 (en) * 2004-07-21 2006-03-02 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2006123097A2 (en) * 2005-05-17 2006-11-23 Millipore Corporation Improved expression elements
WO2007068265A1 (en) * 2005-12-12 2007-06-21 Research Corporation Technologies, Inc. Hybrid 3’ untranslated regions suitable for efficient protein expression in mammalian cells
WO2009155961A1 (en) * 2008-06-27 2009-12-30 King Faisal Specialist Hospital And Research Center Expression vectors based on modified ribosomal protein promoters and uses thereof in post-transcriptional assessment
WO2013143700A2 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2013143698A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
WO2013143699A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
IL131979A0 (en) 1997-03-21 2001-03-19 Enzo Therapeutics Inc Vectors and viral vectors and packaging cell lines for propagating the same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
US7985553B2 (en) 2001-10-29 2011-07-26 Nathaniel Heintz Method for isolating cell type-specific mRNAs
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
EP2500437B1 (en) 2003-01-21 2016-11-30 PTC Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
PL1685251T3 (en) * 2003-10-10 2014-07-31 Powderject Vaccines Inc Nucleic acid constructs
DE102004035227A1 (en) 2004-07-21 2006-02-16 Curevac Gmbh mRNA mixture for vaccination against tumor diseases
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
EP4332227A1 (en) 2005-08-23 2024-03-06 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102006035618A1 (en) 2006-07-31 2008-02-07 Curevac Gmbh New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
WO2008014979A2 (en) 2006-07-31 2008-02-07 Curevac Gmbh NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
DE102006061015A1 (en) 2006-12-22 2008-06-26 Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
SG188104A1 (en) 2008-01-31 2013-03-28 Curevac Gmbh Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
AU2009298501A1 (en) * 2008-09-30 2010-04-08 Abbvie Inc. Improved antibody libraries
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
TWI688395B (en) * 2010-03-23 2020-03-21 英翠克頌公司 Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
ES2558106T3 (en) 2010-07-30 2016-02-02 Curevac Ag Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
DK2611915T3 (en) * 2010-09-01 2015-06-22 Cellagenics B V Nucleic acid fragments from a ribosomal protein promoter to enhance gene expression
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013174409A1 (en) 2012-05-25 2013-11-28 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
RU2712743C2 (en) 2013-08-21 2020-01-30 Куревак Аг Rabies vaccine
BR112016003361A2 (en) 2013-08-21 2017-11-21 Curevac Ag respiratory syncytial virus vaccine (rsv)
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
JP6704850B2 (en) * 2013-12-30 2020-06-03 キュアバック アーゲー Artificial nucleic acid molecule
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007590A2 (en) * 1999-07-27 2001-02-01 Syngenta Participations Ag Chimeric genes for plastid expression
WO2002098443A2 (en) * 2001-06-05 2002-12-12 Curevac Gmbh Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
WO2006022712A1 (en) * 2004-07-21 2006-03-02 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2006123097A2 (en) * 2005-05-17 2006-11-23 Millipore Corporation Improved expression elements
WO2007068265A1 (en) * 2005-12-12 2007-06-21 Research Corporation Technologies, Inc. Hybrid 3’ untranslated regions suitable for efficient protein expression in mammalian cells
WO2009155961A1 (en) * 2008-06-27 2009-12-30 King Faisal Specialist Hospital And Research Center Expression vectors based on modified ribosomal protein promoters and uses thereof in post-transcriptional assessment
WO2013143700A2 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2013143698A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
WO2013143699A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 2 October 2002 (2002-10-02), "Homo sapiens RPL36AL mRNA for ribosomal protein L36a-like, complete cds", XP002699423, Database accession no. AB063609 *
DATABASE NUCLEOTIDE [online] 30 May 1996 (1996-05-30), "Human ribosomal protein L9 mRNA, complete cds.", XP002729678, Database accession no. U09953.1 *
KENMOCHI N ET AL: "A map of 75 human ribosomal protein genes", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, vol. 8, no. 5, 1 May 1998 (1998-05-01), pages 509 - 523, XP002138895, ISSN: 1088-9051 *
LEDDA M ET AL: "Effect of 3'UTR length on the translational regulation of 5'-terminal oligopyrimidine mRNAs", GENE, vol. 344, 3 January 2005 (2005-01-03), ELSEVIER, AMSTERDAM, NL, pages 213 - 220, XP027872598, ISSN: 0378-1119, [retrieved on 20050103] *
MAZURUK K ET AL: "Structural organization and chromosomal localization of the human ribosomal protein L9 gene.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1305, no. 3, 1 March 1996 (1996-03-01), pages 151 - 162, XP002729679, ISSN: 0006-3002 *
MOOR C H D ET AL: "Mechanisms of translational control by the 3' UTR in development and differentiation", SEMINARS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 16, no. 1, 1 February 2005 (2005-02-01), ACADEMIC PRESS, GB, pages 49 - 58, XP004711655, ISSN: 1084-9521, DOI: 10.1016/J.SEMCDB.2004.11.007 *
S. LEVY ET AL: "Oligopyrimidine tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational control.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 88, no. 8, 15 April 1991 (1991-04-15), pages 3319 - 3323, XP055044877, ISSN: 0027-8424, DOI: 10.1073/pnas.88.8.3319 *
WILKIE G S ET AL: "Regulation of mRNA translation by 5'- and 3'-UTR-binding factors", TRENDS IN BIOCHEMICAL SCIENCES, vol. 28, no. 4, 1 April 2003 (2003-04-01), ELSEVIER, HAYWARDS, GB, pages 182 - 188, XP004421226, ISSN: 0968-0004, DOI: 10.1016/S0968-0004(03)00051-3 *

Also Published As

Publication number Publication date
BR112016014462A2 (en) 2017-10-24
CA2927862A1 (en) 2015-07-09
WO2015101414A2 (en) 2015-07-09
RU2016131391A3 (en) 2018-08-23
MX2020003245A (en) 2020-07-20
JP6997251B2 (en) 2022-01-17
US10047375B2 (en) 2018-08-14
CA2927862C (en) 2024-01-23
KR102399799B1 (en) 2022-05-18
SG11201603144QA (en) 2016-07-28
DK3090053T3 (en) 2019-02-25
JP2020184995A (en) 2020-11-19
AU2014375402B2 (en) 2020-10-01
ES2712092T3 (en) 2019-05-09
JP2017502670A (en) 2017-01-26
US20220136001A1 (en) 2022-05-05
CN105874072A (en) 2016-08-17
JP6704850B2 (en) 2020-06-03
RU2717986C2 (en) 2020-03-27
SG10201903381TA (en) 2019-05-30
KR20160104062A (en) 2016-09-02
RU2016131391A (en) 2018-02-02
CN111304231A (en) 2020-06-19
US20170029847A1 (en) 2017-02-02
MX2016008551A (en) 2016-09-26

Similar Documents

Publication Publication Date Title
WO2015101414A3 (en) Artificial nucleic acid molecules
MX2018001040A (en) Artificial nucleic acid molecules.
MX2017008670A (en) Artificial nucleic acid molecules.
MX357803B (en) Artificial nucleic acid molecules.
MX358706B (en) Artificial nucleic acid molecules comprising a 5'top utr.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
MX2019002345A (en) Artificial nucleic acid molecules for improved protein or peptide expression.
IL272850A (en) Novel artificial nucleic acid molecules
IL280652A (en) Nucleic acid molecules and uses thereof for non-viral gene therapy
WO2017077329A3 (en) Nucleic acids, peptides and methods
EA201690529A1 (en) METHODS OF MODIFICATION OF CELL-HOST
WO2019135816A3 (en) Novel nucleic acid modifiers
PH12019500209A1 (en) Methods and compositions for gene expression in plants
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
EA201391109A1 (en) NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE INCLUDING THEM, AND METHODS OF THEIR USE
MX2017009153A (en) Cytokine fusion proteins.
CA3057899A1 (en) Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
EP3604528A4 (en) Cyclic nucleic acid molecule having gene expression control function
EP3448407A4 (en) Dimeric proteins for specific targeting of nucleic acid sequences
DK3260541T3 (en) ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PREPTIDE EXPRESSION
WO2015020993A3 (en) RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
WO2013163085A3 (en) Glycaspis brimblecombei control agents
WO2014053910A3 (en) Gall wasp control agents
PH12021550563A1 (en) Pacas9 nuclease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14854873

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2927862

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014854873

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014854873

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014375402

Country of ref document: AU

Date of ref document: 20141230

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122023004549

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/008551

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016543590

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016014462

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20167020951

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016131391

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016014462

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160620